옵션 체인은 다양한 행사가격과 만기일에 대한 Getty Images Holdings의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Getty Images Holdings에 대한 시장 심리를 평가합니다..

Getty Images Holdings (NYSE:GETY) 주식, 옵션 체인

Getty Images Holdings

Getty Images Holdings Inc is engaged in the core mission of bringing the world's creative and editorial visual content solutions to its customers to engage their audiences. the company has developed market enhancements across e-commerce, content subscriptions, user-generated content, diverse and inclusive content, and proprietary research alongside investment in its technology platform, which includes artificial intelligence and machine learning-driven search functionality and image editing and integrated APIs, to become a trusted industry leader in the visual content. Geographically the company operates in the Americas, Europe, the Middle East, Africa, and Asia-Pacific, out of which a majority of its revenue is generated from the Americas.

Market,Sentiment,,Fear,And,Greed,Index,,Emotional,On,Stock,Market

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

BIDU

CWCO

GETY

SAIC

STNE

CNN 머니 공포·탐욕 지수는 전체 시장 정서에서 약간의 개선을 보여주었지만, 월요일에도 여전히 &#34;극단적 공포&#34; 영역에 머물렀다.미국 주식은 월요일(17일)에 상승세를 보였으며, 다우존스 지수가 거래 중에 350포인트 이상 급등했다. 주요 지수 3개 모두 연속으로 상승했다.

긍정적 경제지표로 다우 지수 350p 상승: 투자자 불안 완화, 탐욕 지수는 &#39;극단적 공포&#39; 영역

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

SGMO

화요일(18일) 미국 지수 선물이 하락세를 보이고 있는 가운데, 오늘 투자자의 주목을 받을 수 있는 주식은 다음과 같다. 화요일 주목해야 할 주식: IHS 홀딩, 헬스에퀴티, 게티 이미지, 상가모 테라퓨틱스 및 스톤

화요일 주목해야 할 주식: IHS 홀딩, 헬스에퀴티, 게티 이미지, 상가모 테라퓨틱스 및 스톤코

월요일(17일) 아침 미국 지수 선물이 하락세를 보이고 있는 가운데, 오늘 투자자 관심을 끌 수 있는 주식은 다음과 같다. 사이언스 어플리케이션, 게티 이미지, 카스텔럼, 콘솔리테이티드 워터 및 타운스퀘어

월요일 주목해야 할 주식: 사이언스 어플리케이션, 게티 이미지, 카스텔럼, 콘솔리테이티드 워터 및 타운스퀘어

Getty Images Holdings, Inc. Class A Common Stock

Getty Images Holdings Inc

U.S. stocks traded lower this morning, with the Dow Jones index falling around 200 points on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.56% to 41,608.14 while the NASDAQ dipped 1.49% to 17,542.81. The S&amp;P 500 also fell, dropping, 0.92% to 5,622.68.
Check This Out: <a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a>
Leading and Lagging Sectors Energy shares jumped by 0.5% on Tuesday.
In trading on Tuesday, consumer discretionary shares fell by 2%.
Top Headline
U.S. industrial production increased by 0.7% in February, surpassing market estimates of 0.2%.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Aditxt, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) shares shot up 57% to $6.88 after the company announced it submitted an application for four new federal funding opportunities.</li>
<li>Shares of Syros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>)got a boost, surging 57% to $0.1351. Syros Pharmaceuticals recently announced a voluntary delisting from the Nasdaq and SEC deregistration.</li>
<li>Heidmar Maritime Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HMR#NASDAQ">HMR</a>) shares were also up, gaining 38% to $3.75.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Avenue Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) shares dropped 46% to $0.4785.</li>
<li>Shares of AirNet Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTE#NASDAQ">ANTE</a>) were down 44% to $0.9017. AirNet Technology recently announced the execution of a non-binding investment LOI with LLP STH Corp, a Kazakstan company.</li>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) was down, falling 37% to $0.0669.</li>
</ul>
Commodities In commodity news, oil traded up 0.5% to $67.94 while gold traded up 1.2% at $3,041.60.
Silver traded up 1.6% to $34.840 on Tuesday, while copper rose 0.7% to $4.9920.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.46%, Germany's DAX 40 jumped 0.63% and France's CAC 40 gained 0.43%. Spain's IBEX 35 Index rose 1.10%, while London's FTSE 100 rose 0.32%.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei gaining 1.20%, China's Shanghai Composite Index gaining 0.11%, Hong Kong's Hang Seng Index surging 2.46% and India's BSE Sensex gaining 1.53%.
Economics
<ul>
<li>U.S. housing starts surged 11.2% month-over-month to an annualized rate of 1.501 million in February following a revised 1.35 million in January.</li>
<li>Building permits declined by 1.2% to an annualized rate of 1.456 million in February.</li>
<li>U.S. import prices increased by 0.4% in February, versus market estimates of a 0.1% decline.</li>
<li>U.S. export prices rose by 0.1% month-over-month in February.</li>
<li>U.S. industrial production increased by 0.7% in February, surpassing market estimates of 0.2%.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44325485/wall-streets-most-accurate-analysts-spotlight-on-3-real-estate-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Real Estate Stocks Delivering High-Dividend Yields</a></li>
</ul>

Equities

Eurozone

Commodities

ADTX

AGMH

ANTE

ATXI

SYRS

Dow Dips Over 200 Points; US Industrial Production Increases More than Expected

Guggenheim analyst Vamil Divan reiterates Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) from Buy to Buy.

Reiteration

Analyst Ratings

Guggenheim Reiterates Buy on Pfizerto Buy

Truist Securities analyst Michael Lewis maintains Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) with a Hold and raises the price target from $17 to $18.

Price Target

SBRA

Truist Securities Maintains Hold on Sabra Health Care REIT, Raises Price Target to $18

Guggenheim analyst Michael Schmidt reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $109 price target.

MRUS

Guggenheim Reiterates Buy on Merus, Maintains $109 Price Target

Truist Securities analyst Michael Lewis maintains Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) with a Hold and raises the price target from $38 to $39.

Truist Securities Maintains Hold on Omega Healthcare Invts, Raises Price Target to $39

Truist Securities analyst Srikripa Devarakonda maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Hold and lowers the price target from $74 to $72.

INCY

Truist Securities Maintains Hold on Incyte, Lowers Price Target to $72

Guggenheim analyst Joseph Osha reiterates Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) with a Buy and maintains $7 price target.

EOSE

Guggenheim Reiterates Buy on Eos Energy Enterprises, Maintains $7 Price Target

Truist Securities analyst Richard Newitter maintains Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) with a Hold and lowers the price target from $90 to $82.

GMED

Truist Securities Maintains Hold on Globus Medical, Lowers Price Target to $82

WIIM

XPEV

XPeng shares are trading lower after the company reported a Q4 Adj EPS miss.

Guggenheim analyst John Difucci maintains Rubrik (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) with a Buy and raises the price target from $76 to $80.

RBRK

Guggenheim Maintains Buy on Rubrik, Raises Price Target to $80

Truist Securities analyst Jailendra Singh maintains Astrana Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTH#NASDAQ">ASTH</a>) with a Buy and lowers the price target from $50 to $46.

ASTH

Truist Securities Maintains Buy on Astrana Health, Lowers Price Target to $46

Earlier this month, Sycamore Partners agreed to acquire Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) for $11.45 per share <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">in cash at closing</a>. Shareholders are also eligible to receive up to $3 in cash per share from the future monetization of Walgreens&#8217; debt and equity interests in VillageMD, which includes the Village Medical, <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44182479/walgreens-stock-rises-as-company-inks-10b-deal-to-go-private" target="_blank" rel="noreferrer noopener">Summit Health and CityMD businesses</a>.
Soon after, Gary Black, managing partner at The Future Fund LLC, said, &#8220;I&#8217;ve talked before about how this company shouldn&#8217;t be public,&#8221; adding that the move is driven by its largest shareholder, executive chairman Stefano Pessina, who <a href="https://www.benzinga.com/markets/equities/25/03/44185847/gary-black-says-walgreens-is-a-company-that-shouldnt-be-public-cites-largest-shareholders-role-in-10-billion-sycamore-deal" target="_blank" rel="noreferrer noopener">holds a 16.9% stake</a>.
The Financial Times, citing sources, writes that Stefano Pessina plans to nearly double his stake in the company to about 30% as part of its acquisition.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43104245/justice-department-accuses-walgreens-of-violating-drug-laws-in-opioid-epidemic-ignored-red-flags-in-opioid-crisis" rel="noreferrer noopener">Justice Department Accuses Walgreens Of Violating Drug Laws In Opioid Epidemic, Ignored Red Flags In Opioid Crisis</a>
The move signals Pessina&#8217;s deepening involvement in the company&#8217;s future, potentially ahead of a breakup of its various business units.
The FT report <a href="https://www.ft.com/content/ef898a28-ed96-45b5-baae-7569b8b778a3" target="_blank" rel="noreferrer noopener">added</a> that the transaction will allow Walgreens to restructure the struggling pharmacy giant. Walgreens is currently in a 35-day window to evaluate competing offers.
Pessina&#8217;s existing stake is worth approximately $2.1 billion. The deal&#8217;s complex financing structure is expected to allow Sycamore to potentially separate Walgreens&#8217; various business units into independent entities, reviving the possibility of selling Boots after <a target="_blank" href="https://www.benzinga.com/m-a/22/01/24860084/bain-capital-reportedly-eyeing-boots-uk-takeover-from-walgreens-report" rel="noreferrer noopener">previous failed attempts</a>.
Walgreens&#8217; market value once exceeded $100 billion following the 2014 merger of Walgreens and Alliance Boots, a deal orchestrated by Pessina. However, the company&#8217;s value has since fallen below $10 billion, facing mounting challenges from online competitors and shifting consumer habits.
Sources indicate that Pessina played a key role in securing the Sycamore deal as he sought a solution to Walgreens&#8217; declining stock price.
In January,&nbsp;Walgreens reported first-quarter sales of $39.46 billion, up 7.5% year over year (+6.9% on constant currency), beating the&nbsp;consensus of $37.28 billion, reflecting sales growth <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/42912519/walgreens-boots-alliance-stock-jumps-on-better-than-expected-q1-earnings-sticks-to-annual-profit-forecast" rel="noreferrer noopener">across all segments</a>.
Analysts estimate Walgreens&#8217; second quarter 2025 adjusted EPS of 53 cents, with sales of $37.9 billion. Wall Street forecasts 2025 adjusted EPS of $1.61 and <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">sales of $151.6 billion</a>.
Price Action: WBA stock is down 0.04% at $11.26&nbsp;at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44375647/canadian-cannabis-sndl-achieves-break-even-free-cash-flow-for-2024" target="_blank" rel="noreferrer noopener">Canadian Cannabis SNDL Achieves Break-Even Free Cash Flow For 2024</a></li>
</ul>
Photo: Shutterstock

Large Cap

Health Care

General

Walgreens' Executive Chair Stefano Pessina Seeks To Strengthen Control With Nearly Double Stake

Regencell Bioscience Shares Halted On Circuit Breaker To The Downside, Stock Now Up 27.5%

Guggenheim analyst Michael Schmidt downgrades Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Buy to Neutral and maintains the price target from $92 to $92.

Downgrades

Guggenheim Downgrades Incyte to Neutral, Maintains Price Target to $92

Truist Securities analyst Ki Bin Kim maintains Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) with a Hold and lowers the price target from $316 to $310.

Truist Securities Maintains Hold on Public Storage, Lowers Price Target to $310

Compass Point analyst Casey Alexander maintains TriplePoint Venture Gwth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPVG#NYSE">TPVG</a>) with a Neutral and lowers the price target from $8 to $7.25.

TPVG

Compass Point Maintains Neutral on TriplePoint Venture Gwth, Lowers Price Target to $7.25

Truist Securities analyst Ki Bin Kim maintains EPR Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>) with a Hold and raises the price target from $46 to $51.

Truist Securities Maintains Hold on EPR Props, Raises Price Target to $51

Guggenheim analyst Curry Baker initiates coverage on Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) with a Buy rating and announces Price Target of $12.

Initiation

GENI

Guggenheim Initiates Coverage On Genius Sports with Buy Rating, Announces Price Target of $12

Deep-pocketed investors have adopted a bearish approach towards Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MU usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Micron Technology. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 13% leaning bullish and 80% bearish. Among these notable options, 8 are puts, totaling $565,394, and 7 are calls, amounting to $354,723.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $70.0 to $120.0 for Micron Technology over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Micron Technology's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Micron Technology's substantial trades, within a strike price spectrum from $70.0 to $120.0 over the preceding 30 days.
<h3>Micron Technology 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742306474_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.35</td>
<td>$4.25</td>
<td>$4.25</td>
<td>$99.00</td>
<td>$210.8K</td>
<td>607</td>
<td align="right">543</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.85</td>
<td>$4.7</td>
<td>$4.65</td>
<td>$100.00</td>
<td>$93.6K</td>
<td>12.9K</td>
<td align="right">217</td>
</tr>
<tr>
<td>MU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$40.2</td>
<td>$39.8</td>
<td>$39.8</td>
<td>$70.00</td>
<td>$79.6K</td>
<td>865</td>
<td align="right">0</td>
</tr>
<tr>
<td>MU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$8.5</td>
<td>$8.4</td>
<td>$8.4</td>
<td>$100.00</td>
<td>$77.2K</td>
<td>14.1K</td>
<td align="right">110</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/17/27</td>
<td>$24.1</td>
<td>$23.1</td>
<td>$23.9</td>
<td>$100.00</td>
<td>$69.3K</td>
<td>105</td>
<td align="right">29</td>
</tr>
</tbody>
</table>

<h3>About Micron Technology</h3>
Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated.
After a thorough review of the options trading surrounding Micron Technology, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Micron Technology</h3>
<ul>
<li>With a volume of 1,886,364, the price of MU is down -1.9% at $101.15. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 2 days.</li>
</ul>
<h3>What The Experts Say On Micron Technology</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $128.33.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Micron Technology with a target price of $130. 
&#x2A; In a cautious move, an analyst from Wedbush downgraded its rating to Outperform, setting a price target of $125. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Micron Technology, which currently sits at a price target of $130. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Micron Technology options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Micron Technology's Options Frenzy: What You Need to Know

Deep-pocketed investors have adopted a bullish approach towards XPeng (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in XPEV usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for XPeng. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 66% leaning bullish and 11% bearish. Among these notable options, 4 are puts, totaling $150,960, and 5 are calls, amounting to $276,030.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $10.0 to $35.0 for XPeng over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in XPeng's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to XPeng's substantial trades, within a strike price spectrum from $10.0 to $35.0 over the preceding 30 days.
<h3>XPeng Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742306468_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>XPEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$3.1</td>
<td>$2.73</td>
<td>$3.0</td>
<td>$35.00</td>
<td>$114.0K</td>
<td>6.6K</td>
<td align="right">404</td>
</tr>
<tr>
<td>XPEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.9</td>
<td>$5.35</td>
<td>$5.83</td>
<td>$18.00</td>
<td>$58.2K</td>
<td>277</td>
<td align="right">100</td>
</tr>
<tr>
<td>XPEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$3.45</td>
<td>$3.15</td>
<td>$3.3</td>
<td>$19.00</td>
<td>$46.2K</td>
<td>1.0K</td>
<td align="right">145</td>
</tr>
<tr>
<td>XPEV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$4.6</td>
<td>$4.45</td>
<td>$4.5</td>
<td>$22.00</td>
<td>$45.0K</td>
<td>902</td>
<td align="right">337</td>
</tr>
<tr>
<td>XPEV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/17/25</td>
<td>$4.5</td>
<td>$4.15</td>
<td>$4.31</td>
<td>$22.00</td>
<td>$43.0K</td>
<td>902</td>
<td align="right">227</td>
</tr>
</tbody>
</table>

<h3>About XPeng</h3>
Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 141,000 EVs in 2023, accounting for about 2% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
<h3>XPeng's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 6,931,461, the XPEV's price is down by -8.73%, now at $22.41. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 0 days.</li>
</ul>
<h3>Professional Analyst Ratings for XPeng</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $23.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Showing optimism, an analyst from UBS upgrades its rating to Neutral with a revised price target of $18. 
&#x2A; An analyst from Citigroup has elevated its stance to Buy, setting a new price target at $29. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest XPeng options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

A Closer Look at XPeng's Options Market Dynamics

Legal

Press Releases

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates GETY, NARI, SSY on Behalf of Shareholders

Kuehn Law Encourages VINC, NEUE, GETY, and CLBR Investors to Contact Law Firm

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates GETY, CLBR, VINC, NEUE on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TURN, DFS, GETY on Behalf of Shareholders

Getty Images and Verizon to Award $20,000 Grant to Champion Disability Representation in the Workplace

Financing

Getty Images Holdings, Inc. Announces Comprehensive Refinancing of Approximately $1.042 Billion Existing Term Loans

Getty Images to Release Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025

Sports

Getty Images and UEFA Renew Multi-Year Agreement

Getty Images Signs Multi-Year Photography Partnership with the National Women's Soccer League

Getty Images Reports Fourth Quarter and Full Year 2024 Results

CLBR

NARI

NEUE

TURN

VINC

Angi

Bumble

Cars.com

Trump Media & Technology Group Corp. - Warrants

Trump Media & Technology

EverQuote

FuboTV

Nextdoor Holdings, Inc. Class A Common Stock

Nextdoor Holdings

MediaAlpha

Hello Group Inc. - American Depositary Shares

Hello Gr

Outbrain

QuinStreet

Shutterstock

Taboola.com

Tripadvisor

TrueCar

trivago N.V. - American Depositary Shares

trivago

Travelzoo

Vimeo

Vtex

WEBTOON Entertainment Inc. - Common stock

Webtoon Entertainment

Yalla Group Limited American Depositary Shares, each representing one Class A Ordinary Share

Yalla Group

Yelp

Ziff Davis

Zhihu Inc. American Depositary Shares, each representing three (3) Class A Ordinary Shares

Comments

Getty Images Holdings

Getty Images Holdings (GETY) 옵션

Getty Images Holdings (NYSE:GETY) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌